CA2926771C - Cancer treatment with combination of plinabulin and taxane - Google Patents
Cancer treatment with combination of plinabulin and taxane Download PDFInfo
- Publication number
- CA2926771C CA2926771C CA2926771A CA2926771A CA2926771C CA 2926771 C CA2926771 C CA 2926771C CA 2926771 A CA2926771 A CA 2926771A CA 2926771 A CA2926771 A CA 2926771A CA 2926771 C CA2926771 C CA 2926771C
- Authority
- CA
- Canada
- Prior art keywords
- docetaxel
- plinabulin
- npi
- tumor
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/085075 WO2015051543A1 (en) | 2013-10-11 | 2013-10-11 | Cancer treatment with combination of plinabulin and taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2926771A1 CA2926771A1 (en) | 2015-04-16 |
| CA2926771C true CA2926771C (en) | 2022-07-05 |
Family
ID=52812462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2926771A Active CA2926771C (en) | 2013-10-11 | 2013-10-11 | Cancer treatment with combination of plinabulin and taxane |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10596169B2 (enExample) |
| EP (1) | EP3076972B1 (enExample) |
| JP (1) | JP6411523B2 (enExample) |
| KR (1) | KR102225371B1 (enExample) |
| CN (1) | CN105705148B (enExample) |
| AU (1) | AU2013402794B2 (enExample) |
| BR (1) | BR112016007946A2 (enExample) |
| CA (1) | CA2926771C (enExample) |
| DK (1) | DK3076972T3 (enExample) |
| ES (1) | ES2902665T3 (enExample) |
| IL (1) | IL244984B (enExample) |
| MX (1) | MX384751B (enExample) |
| MY (1) | MY185650A (enExample) |
| NZ (1) | NZ719049A (enExample) |
| RU (1) | RU2662298C2 (enExample) |
| SG (1) | SG11201602637QA (enExample) |
| WO (1) | WO2015051543A1 (enExample) |
| ZA (1) | ZA201602380B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL286282B2 (en) * | 2015-02-12 | 2023-10-01 | Beyondspring Pharmaceuticals Inc | Use of palinabolin in combination with immune checkpoint inhibitors |
| HK1249052A1 (zh) * | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗与ras突变相关的癌症的方法 |
| EP3265091A4 (en) * | 2015-03-06 | 2018-08-01 | Beyondspring Pharmaceuticals Inc. | Method of treating a brain tumor |
| MX376122B (es) * | 2015-07-13 | 2025-03-07 | Beyondspring Pharmaceuticals Inc | Composiciones de plinabulina. |
| SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| BR112018074990A2 (pt) * | 2016-06-06 | 2019-03-12 | Beyondspring Pharmaceuticals, Inc. | composição, usos e método para reduzir neutropenia |
| US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| EP3576733A4 (en) * | 2017-02-01 | 2020-11-25 | Beyondspring Pharmaceuticals, Inc. | NEUTROPENIA REDUCTION METHOD |
| BR112019018880A2 (pt) * | 2017-03-13 | 2020-04-14 | Beyondspring Pharmaceuticals Inc | composições de plinabulina e seu uso |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| CN112105363A (zh) * | 2018-02-01 | 2020-12-18 | 大连万春布林医药有限公司 | 用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法 |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| JP2018199726A (ja) * | 2018-09-26 | 2018-12-20 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| JP2022513038A (ja) * | 2018-11-14 | 2022-02-07 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合薬を使用する癌の治療方法 |
| CN110507653B (zh) * | 2019-08-02 | 2022-12-02 | 北京赛而生物药业有限公司 | 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用 |
| US20240299377A1 (en) * | 2019-10-15 | 2024-09-12 | Beyondspring Pharmaceuticals, Inc. | Methods and compositions for treating iron disorders |
| EP4319751A4 (en) | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) * | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| DK1529044T5 (da) | 2002-08-02 | 2008-04-21 | Nereus Pharmaceuticals Inc | Dehydrophenylahistiner og analoger deraf og syntesen af dehydrophenylahistiner og analoger deraf |
| JP2007520565A (ja) * | 2004-02-04 | 2007-07-26 | ネレアス ファーマシューティカルズ インコーポレイテッド | デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成 |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| WO2014160183A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
-
2013
- 2013-10-11 ES ES13895342T patent/ES2902665T3/es active Active
- 2013-10-11 MY MYPI2016000620A patent/MY185650A/en unknown
- 2013-10-11 JP JP2016547208A patent/JP6411523B2/ja active Active
- 2013-10-11 CN CN201380080185.5A patent/CN105705148B/zh active Active
- 2013-10-11 DK DK13895342.7T patent/DK3076972T3/da active
- 2013-10-11 KR KR1020167012255A patent/KR102225371B1/ko active Active
- 2013-10-11 RU RU2016112608A patent/RU2662298C2/ru active
- 2013-10-11 SG SG11201602637QA patent/SG11201602637QA/en unknown
- 2013-10-11 CA CA2926771A patent/CA2926771C/en active Active
- 2013-10-11 BR BR112016007946A patent/BR112016007946A2/pt not_active Application Discontinuation
- 2013-10-11 NZ NZ719049A patent/NZ719049A/en unknown
- 2013-10-11 AU AU2013402794A patent/AU2013402794B2/en active Active
- 2013-10-11 WO PCT/CN2013/085075 patent/WO2015051543A1/en not_active Ceased
- 2013-10-11 EP EP13895342.7A patent/EP3076972B1/en active Active
- 2013-10-11 US US15/028,376 patent/US10596169B2/en active Active
- 2013-10-11 MX MX2016004441A patent/MX384751B/es unknown
-
2016
- 2016-04-07 IL IL244984A patent/IL244984B/en unknown
- 2016-04-08 ZA ZA2016/02380A patent/ZA201602380B/en unknown
-
2020
- 2020-03-17 US US16/821,348 patent/US20200281921A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015051543A1 (en) | 2015-04-16 |
| JP2016536352A (ja) | 2016-11-24 |
| KR20160078987A (ko) | 2016-07-05 |
| MX384751B (es) | 2025-03-14 |
| MY185650A (en) | 2021-05-27 |
| AU2013402794B2 (en) | 2020-02-27 |
| ES2902665T3 (es) | 2022-03-29 |
| JP6411523B2 (ja) | 2018-10-24 |
| AU2013402794A1 (en) | 2016-05-12 |
| DK3076972T3 (da) | 2022-01-03 |
| IL244984B (en) | 2022-05-01 |
| US10596169B2 (en) | 2020-03-24 |
| EP3076972A4 (en) | 2017-12-20 |
| RU2662298C2 (ru) | 2018-07-25 |
| US20200281921A1 (en) | 2020-09-10 |
| BR112016007946A2 (pt) | 2017-09-12 |
| CA2926771A1 (en) | 2015-04-16 |
| ZA201602380B (en) | 2022-05-25 |
| KR102225371B1 (ko) | 2021-03-10 |
| CN105705148A (zh) | 2016-06-22 |
| IL244984A0 (en) | 2016-05-31 |
| EP3076972B1 (en) | 2021-10-06 |
| SG11201602637QA (en) | 2016-05-30 |
| MX2016004441A (es) | 2016-10-28 |
| EP3076972A1 (en) | 2016-10-12 |
| CN105705148B (zh) | 2021-03-23 |
| WO2015051543A8 (en) | 2016-04-21 |
| US20160250209A1 (en) | 2016-09-01 |
| NZ719049A (en) | 2020-06-26 |
| RU2016112608A (ru) | 2017-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2926771C (en) | Cancer treatment with combination of plinabulin and taxane | |
| CA2672933A1 (en) | Method of treating cancer by a combined therapy of anticancer agents | |
| AU2021218871B2 (en) | Use of mitoxantrone hydrochloride liposome for treating breast cancer | |
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| WO2016168451A1 (en) | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment | |
| JP2013521338A (ja) | 小細胞肺癌を治療するための方法 | |
| Kollmannsberger et al. | Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179) | |
| Coronel et al. | A randomized comparison of cisplatin and oral vinorelbine as radiosensitizers in aged or comorbid locally advanced cervical cancer patients | |
| JP2026001134A (ja) | ミトキサントロン塩酸塩リポソームの応用 | |
| JP2018199726A (ja) | プリナブリン及びタキサンの組合せがん治療 | |
| HK1229712B (en) | Cancer treatment with combination of plinabulin and taxane | |
| TW202102211A (zh) | 用於使用６，８－雙－苄硫基－辛酸治療淋巴瘤之治療方法及組成物 | |
| BR112020011796A2 (pt) | uso de tratamento combinado de anticorpo pd-1 e apati-nib para o tratamento de câncer de mama negativo triplo | |
| WO2025208442A1 (en) | Methods of treatment of immune thrombocytopenia using sovleplenib | |
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies | |
| HK40082294A (en) | Uses of mitoxantrone hydrochloride liposome | |
| WO2025232873A1 (zh) | 多西他赛白蛋白组合物治疗胃癌或胃食管结合部癌的用途 | |
| WO2025082356A1 (zh) | Cldn18_2抗体与化学治疗药物的组合及其应用 | |
| WO2026037393A1 (zh) | 一种抗体药物偶联物与酪氨酸激酶抑制剂的组合 | |
| EP4304645A1 (en) | Use of oregovomab and bevacizumab, paclitaxel, carboplatin for treatment of brca-wild type platinum sensitive recurrent | |
| CA3227813A1 (en) | Pharmaceutical composition for treating solid tumors | |
| JP2026506073A (ja) | エフロルニチンを使用する組成物および方法 | |
| Vardi et al. | The feasibility of early administration of combination chemotherapy following cytoreductive surgery and second-look operation in patients with stage III ovarian carcinoma: A pilot study | |
| HK1261494A1 (en) | Use of combination of vegfr inhibitor and parp inhibitor in preparation of medicament for treating gastric cancer | |
| HK1155089A (en) | Use of picoplatin and bevacizumab to treat colorectal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20181004 |
|
| EEER | Examination request |
Effective date: 20181004 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240904 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240904 |